News & Analysis as of

Pharmaceutical Industry Financial Reporting

Goodwin

Formycon Q1 2022 Financial Results and Announcement of Two New Biosimilar Products

Goodwin on

Formycon recently announced its sales and earnings figures for the first quarter of 2022.  Earnings before interest, taxes, depreciation and amortization (EBITDA) amounted to EUR -4.0 million (Q1/previous year: EUR -1.7...more

Goodwin

Q1 2021 Earnings Roundup: Biologics and Biosimilars Update

Goodwin on

Below are some highlights from first quarter 2021 earnings reports recently released by biologics and biosimilars companies...more

Goodwin

Q4 2020 and Full Year Earnings Roundup: Biologics and Biosimilars Update

Goodwin on

​​​​​​​Below are some highlights from fourth quarter and full year 2020 earnings reports recently released by biologics and biosimilars companies...more

Mayer Brown Free Writings + Perspectives

Recent SEC Enforcement Actions Involving Accounting Misstatements and Non-GAAP Financial Measures

In July  2020, a publicly traded pharmaceutical company entered into a settlement with the Securities and Exchange Commission, without admitting or denying findings, and agreed to pay a financial penalty relating to various...more

Robins Kaplan LLP

Financial Daily Dose 7.12.2019 | Top Story: Amazon to Spend $700M Retraining 100,000 Workers

Robins Kaplan LLP on

Amazon announced this week that it will spend $700 million to retrain a third of its US workforce to adapt to the increasing amount of robotic and automation technology in its warehouses.  The 6-year effort will eventually...more

King & Spalding

Increasing Attention on Physicians Failing to Disclose Financial Relationships with Drug Companies in Medical Journal Publications

King & Spalding on

On December 8, 2018, ProPublica and The New York Times published an article describing failures by several prominent physicians to disclose their financial relationships with drug companies in studies they published in...more

The Volkov Law Group

Fixing a Sour Corporate Culture: Valeant Pharmaceuticals Faces an Uphill Challenge

The Volkov Law Group on

Like the Greek mythology character Sisyphus, Valeant Pharmaceutical is attempting to atone for its sins and turn its corporate culture around. I am not usually a cynic but when I see these transparent attempts to reverse a...more

7 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide